NCT05757700View on ClinicalTrials.gov

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

February 23, 2026

Study Completion Date

February 23, 2026

Conditions
B-Cell LymphomaLarge B-cell LymphomaDLBCL, Nos Genetic SubtypesHigh-grade B Cell LymphomaMediastinal Large B-cell Lymphoma
Interventions
BIOLOGICAL

19(T2)28z1xx TRAC T cell

"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER